Phillip Gould

Virology, gene regulation particularly focussing on protein translation and commercialisation of science

Dr Phillip Gould’s is Associate Head of School (Enterprise and Innovation) and his research interests is based around the molecular characterisation of respiratory viruses. This includes targeting key host and viral proteins with novel therapeutics synthesised by Dr Andrew Marsh (Chemistry Department Warwick University).  Phil is also founder and CSO of OVO Biotherapeutics which is a newly formed spin out company from Coventry University. OVO Biotherapeutics have developed a platform technology that supports viral vaccine companies to generate increased manufacturing yields in faster timescales. OVO is currently being funded through a combination of enterprise grants and venture capitalist funds. Within this research community is Dr William Collier who now works for OVO and 3 PhD students. With the addition of new funds OVO is currently recruiting two additional postdoctoral scientists including a specialised bioinformatician.

Based around the current COVID-19 pandemic Phil is also involved in a number of collaborative projects with Engineering (Coventry University) and external companies looking at anti-viral surfaces.